Greenpharma Listed by thegentlemen Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Greenpharma, a Brazilian pharmaceutical manufacturer, was listed on April 19, 2026, by the ransomware group thegentlemen. The listing states that internal files were exfiltrated during a ransomware attack. The number of individuals whose information may be involved remains unknown, and no further details on the volume or specific contents of the data have been released. The incident highlights the exposure risks that arise when organisations holding regulated health-related records face ransomware operations that combine encryption with data theft.

Inside the incident

The only confirmed information is the April 19, 2026 listing on the group’s site and the statement that internal files were taken. No figure for the number of people affected has been published. The timing of the intrusion, the method of initial access, and whether any ransom demand was issued or met are not disclosed in available reports.

Inside thegentlemen

Thegentlemen is a ransomware group that maintains a public leak site to list organisations from which it claims to have obtained data. Such groups commonly encrypt systems after copying files and then pressure victims by threatening to publish the material. The listing of Greenpharma constitutes the group’s claim of involvement; independent confirmation of the data’s authenticity or scope has not been provided.

Greenpharma and its sector

Greenpharma Química & Farmacêutica was founded in 1989 in Anápolis, Goiás, and acquired in 1995 by industrial pharmacist Eduardo Gonçalves. It produces generic and over-the-counter medicines, distributes them through pharmacies and hospitals across Brazil, and operates its own ANVISA-accredited pharmaceutical equivalence laboratory, EQFAR-21. Pharmaceutical manufacturers routinely maintain records that include product formulations, quality-control data, supplier contracts, and internal communications, in addition to any employee or partner information required for regulatory compliance.

What was likely exposed

The listing refers only to “internal files.” The precise categories of data have not been published. Organisations of this type typically store manufacturing records, laboratory results, distribution logs, and administrative documents; whether any of these categories, or personal data, were among the exfiltrated material remains unconfirmed.

Why it matters

Pharmaceutical records can contain proprietary process information and, in some cases, personal details tied to employees, clinical partners, or regulatory filings. If such material circulates without context or verification, it can create operational, commercial, or privacy consequences for the organisation and for any individuals named in the files. The absence of a confirmed count of affected people leaves the scale of personal impact unknown.

Were you affected?

Individuals who have interacted with Greenpharma as employees, suppliers, or partners have no public confirmation mechanism at present. Practical steps include monitoring official statements from the company and reviewing any direct correspondence received from it.

• Change passwords for any accounts linked to the organisation and enable multi-factor authentication where available.
• Watch for unusual activity in financial or health-related accounts.
• Use a free exposure scan of your email address against known breach data sets to check for prior appearances of your information.

AICompiled with AI assistance from public sources and published under our editorial standards.